Diabetic Foot Ulcers - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Diabetic Foot Ulcers - Pipeline Review, H2 2018’, provides an overview of the Diabetic Foot Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers

- The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects

- The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Anterogen Co Ltd

CardioVascular BioTherapeutics Inc

Celularity Inc

Cynata Therapeutics Ltd

CytoTools AG

Energenesis Biomedical Co Ltd

EyeGene Inc

Factor Therapeutics Ltd

FirstString Research Inc ...

Anterogen Co Ltd

CardioVascular BioTherapeutics Inc

Celularity Inc

Cynata Therapeutics Ltd

CytoTools AG

Energenesis Biomedical Co Ltd

EyeGene Inc

Factor Therapeutics Ltd

FirstString Research Inc

Genentech Inc

Human Stem Cells Institute

Lakewood-Amedex Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Oneness Biotech Co Ltd

Pherecydes Pharma SA

ProMetic Life Sciences Inc

Promore Pharma AB

Shionogi & Co Ltd

Stempeutics Research Pvt Ltd

SynDermix AG

TechnoPhage SA

Topadur Pharma AG

USV Pvt Ltd

ViroMed Co Ltd

ZZ Biotech LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Foot Ulcers - Overview 6

Diabetic Foot Ulcers - Therapeutics Development 7

Diabetic Foot Ulcers - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Foot Ulcers - Overview 6

Diabetic Foot Ulcers - Therapeutics Development 7

Diabetic Foot Ulcers - Therapeutics Assessment 17

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 25

Diabetic Foot Ulcers - Drug Profiles 37

Diabetic Foot Ulcers - Dormant Projects 118

Diabetic Foot Ulcers - Discontinued Products 122

Diabetic Foot Ulcers - Product Development Milestones 123

Appendix 132

List of Tables

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 14 ...

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 14

Number of Products under Development by Universities/Institutes, H2 2018 17

Products under Development by Companies, H2 2018 18

Products under Development by Universities/Institutes, H2 2018 21

Number of Products by Stage and Target, H2 2018 23

Number of Products by Stage and Mechanism of Action, H2 2018 25

Number of Products by Stage and Route of Administration, H2 2018 27

Number of Products by Stage and Molecule Type, H2 2018 29

Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, H2 2018 30

Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H2 2018 30

Diabetic Foot Ulcers - Pipeline by Celularity Inc, H2 2018 31

Diabetic Foot Ulcers - Pipeline by Cynata Therapeutics Ltd, H2 2018 31

Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2018 32

Diabetic Foot Ulcers - Pipeline by Energenesis Biomedical Co Ltd, H2 2018 32

Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H2 2018 32

Diabetic Foot Ulcers - Pipeline by Factor Therapeutics Ltd, H2 2018 33

Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H2 2018 33

Diabetic Foot Ulcers - Pipeline by Genentech Inc, H2 2018 34

Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2018 34

Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H2 2018 34

Diabetic Foot Ulcers - Pipeline by MallInckrodt Plc, H2 2018 35

Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H2 2018 35

Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2 2018 36

Diabetic Foot Ulcers - Pipeline by OliX Pharmaceuticals Inc, H2 2018 36

Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H2 2018 37

Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H2 2018 37

Diabetic Foot Ulcers - Pipeline by ProMetic Life Sciences Inc, H2 2018 38

Diabetic Foot Ulcers - Pipeline by Promore Pharma AB, H2 2018 38

Diabetic Foot Ulcers - Pipeline by Shionogi & Co Ltd, H2 2018 38

Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H2 2018 39

Diabetic Foot Ulcers - Pipeline by SynDermix AG, H2 2018 39

Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2018 40

Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H2 2018 40

Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H2 2018 40

Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H2 2018 41

Diabetic Foot Ulcers - Pipeline by ZZ Biotech LLC, H2 2018 41

Diabetic Foot Ulcers - Dormant Projects, H2 2018 123

Diabetic Foot Ulcers - Discontinued Products, H2 2018 127

List of Figures

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 13 ...

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products by Top 10 Targets, H2 2018 22

Number of Products by Stage and Top 10 Targets, H2 2018 22

Number of Products by Top 10 Mechanism of Actions, H2 2018 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 24

Number of Products by Routes of Administration, H2 2018 26

Number of Products by Stage and Routes of Administration, H2 2018 26

Number of Products by Top 10 Molecule Types, H2 2018 28

Number of Products by Stage and Top 10 Molecule Types, H2 2018 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports